Living with Filariasis: Unseen Struggles of a Neglected Disease

Abstract

Lymphatic filariasis (LF) is a long-lasting, debilitating parasitic infection that has remained an immense burden to the endemic areas globally in the realms of physical, psychological, and socioeconomic suffering. LF presents itself in the form of lymphedema, hydrocele, and disfigurement, and limits motor activity, working capabilities, and interaction processes between people, significantly reducing self-esteem and life quality. LF brings significant socio-psychological distress besides the physical one. A decline in self-esteem often results in anxiety and depression; recognizable deformities are stigmatized and avoided. This social isolation and poverty become internalized, also with the misconceptions of contagion and impurity, and further bring about the perpetuation of vulnerability. Gender acts as a multifactor determinant force of the LF experience. It contains multiple layers of discrimination against women, concerning marriage refusal, and the workplace, where men are denied opportunities to earn their living and can become social outcasts. Such inequities, which are gender-based, are expected to be addressed when it comes to managing diseases. Constant obstacles put access to timely treatment and care in the spotlight, including the lack of awareness, financial constraints, and health facilities. The most effective interventions are the extension of the community participation levels and maximization of mass drug administration (MDA), which can considerably decrease the disease and burden of the disease and its burden. The world campaigns towards the abolition should not henceforth be geared towards pharmacological but rather take a rights-based approach. The psychological support, social rehabilitation, and gender-based interventions introduced into the social health systems can increase the inclusion and cost-efficiency of the individuals who have already experienced the widened perceived effects of LF and their dignity.

Introduction

Elephantiasis is a disfiguring disease and is caused by a bite of an infected mosquito—it is known as lymphatic filariasis (LF). These tiny thread-like worms infect, causing damage to the lymphatic system, and are known as Wuchereria bancrofti, Brugia malayi, and Brugia timori. These infections damage the lymphatic system. In the long run, this causes chronic swelling (primarily in the legs, arms, breasts, or genitals), which causes severe disfigurement and disability. All these physical transformations are painful and have a serious impact on the quality of an individual [1].

LF is one of the most significant community health issues in Asia, Africa, South America, and the Pacific. Over 120 million individuals were reported to have been infected as of the year 2000, with an estimated 40 million left chronically disabled by the disease. It is regarded as the second leading cause of long-term and irreversible disability in most endemic regions. In this, the global interventions such as the Global Programme to Eliminate Lymphatic Filariasis (GPELF), initiated the Mass Drug Administration (MDA) and Transmission Assessment Surveys (TAS) to both stop transmission and decrease the burden of disease.

According to the report by the Union Health Ministry of 2020, India carries the largest portion of this burden, with almost 40 percent of the total number of cases in the world. The World Health Organization (WHO) estimates that there are about 404 million people at risk of LF in India, out of 657 million people affected all over the world. The disease is also prevalent among the economically underprivileged who reside mostly in a few states like Bihar, Jharkhand, Odisha, and in some districts of Uttar Pradesh [2]. Sanitary mismanagement, lack of health care facilities, and untreated mosquito breeding sites have been a cause of its further spread in these locations.

Although prevalent, LF is still considered a Neglected Tropical Disease (NTD), indicating not only its prioritization in low-income areas but also insufficient focus on it in the global healthcare agenda. The social and psychological consequences are quite neglected, whereas the physical symptoms are visible and hence tend to attract attention.

The sufferers of LF are socially stigmatized and isolated, and their decisions and opportunities of working, marrying, and living in the community are limited. This seclusion results in suffering behind closed doors – expression of depression, anxiety, and low self-esteem – to add to their physiological struggle.

Therefore, addressing LF effectively requires not only medical interventions to eliminate the infection but also strategies to confront the deep-rooted social and psychological challenges faced by affected individuals [1].

Treatment Available

Medical Management of LF

Microfilaricidal Agents

Diethylcarbamazine (DEC) - DEC primarily targets microfilariae by modifying them so tissue-resident monocytes can engulf them more easily, while circulating phagocytes play a lesser role. DEC acts on microfilariae and adult worms, modulating arachidonic acid metabolism and enhancing phagocytosis. DEC was administered in a dosage of 6mg/kg/day for 12-day course. Corticosteroids are often co-administered to minimize allergic reactions caused by rapid microfilarial breakdown [2].

Ivermectin - Ivermectin, a potent anthelmintic derivative of Streptomyces avermitilis, targets the glutamate-gated chloride channels in nematodes, which are absent in flukes and tapeworms, making it ineffective against these parasites. It also enhances GABAergic transmission within worms, causing tonic paralysis. The adult dose is 150–200 μg/kg single dose annually [3].

Anti-nematode (gut-targeting) Agents

Mebendazole and Flubendazole - These drugs irreversibly inhibit glucose uptake by nematodes, depleting glycogen stores, reducing ATP production, and eventually causing parasite death. They do not affect human blood glucose levels [2]. The adult dose is 100 mg orally twice daily for 3 days, with a possible repeat after 3 weeks if symptoms persist.

Albendazole - Albendazole binds selectively to beta-tubulin in parasite cells, disrupting microtubule polymerization, which inhibits glucose absorption and reduces ATP production. This leads to energy depletion, paralysis, and death of the worms [4]. The standard adult dose is 400 mg orally.

Triple-Drug Therapy (IDA)

Recent studies have demonstrated that the combination of ivermectin, DEC, and albendazole (IDA) is more effective than dual therapies in clearing microfilariae [5], and also has reported a 63% reduction in community antigenemia prevalence following two annual rounds of IDA, with clearance rates reaching 68.4% at 4 months post-treatment.

The World Health Organization (WHO) has endorsed IDA for accelerating LF elimination in areas where onchocerciasis is not co-endemic.

Cost-Effectiveness and Modelling Studies

A cost-effective trial evaluated lowering the antigen prevalence threshold for stopping MDA in LF programs. It was found that reducing the threshold of microfilaria from <1% to <0.5% increases the probability of elimination and, although it may slightly increase short-term costs, it is cost-effective in the long term across various prevalence and coverage settings [6].

An implementation trial of IDA triple-drug therapy in Southern India was conducted and found that the three-drug regimen cleared microfilariae more effectively than dual therapy [7]. The study also highlighted the need for updated monitoring and evaluation strategies to track the impact of IDA-MDA for LF elimination.

Moxidectin as an Alternative

Moxidectin, a newer macrocyclic lactone, has shown promise as an alternative to ivermectin. It has a longer half-life and better microfilaricidal activity, potentially reducing the number of required treatments [8].

Surgical management - The two primary surgical approaches for limb lymphedema are drainage and excisional procedures. Drainage techniques aim to improve lymph flow by either creating a detour around the blockage—for example, through lymphovenous anastomosis—or by establishing new lymphatic pathways, such as with omental transposition. Excisional procedures, meanwhile, focus on reducing the size of the swollen limb by surgically removing excess tissue. These methods differ in how and where incisions are made, how the skin is covered afterwards, and whether the surgery is done in one or multiple stages. Homan’s procedure [9], for instance, involves removing tissue from around the entire leg over two to four separate sessions, while other procedures attempt to combine features of drainage and excision in a single operation.

Social Stigma –The Hidden Burden

LF imposes not only physical burdens but also profound social and psychological burdens, particularly in endemic regions like India. The visible manifestations of LF, such as lymphedema, often lead to social ostracization, discrimination, and psychological distress.

Enacted stigma refers to the experience of discrimination faced by individuals. In many communities, people with LF are shunned, considered cursed, or blamed for their condition. This stigma can isolate individuals from family, friends, and work due to the psychological burden.

Perceived stigma is the realization and expectation of the ailing member of society that they are going to receive negative attitudes regarding their illness. Although no one is discriminated against, the fear of being judged might result in them shunning any social interaction, and they do not want to seek treatment [3].

Self-stigma, also referred to as internalized stigma, in which the individual internalizes negative stereotypes, leading to shame, low self-esteem, and worthlessness, which prevents treatment-seeking behavior [5].

A study conducted in Tamil Nadu revealed that 87% of LF patients perceived some level of social stigma, highlighting its pervasive nature of this issue. This stigma extends beyond social exclusion, affecting mental health and economic opportunities. Research indicates that individuals with LF-related disabilities experience higher levels of poor mental well-being compared to the general community. The psychological impact includes depression, anxiety, and a diminished quality of life [10]. Women were more emotionally distressed, which sometimes resulted in suicidal ideation due to economic and social hardship [4].

The weight of LF calculated based on global values is one of the major methods of highlighting its value. LF is a major cause of millions of disability-adjusted life years (DALYs) annually, with a large portion of the contribution being to chronic lymphedema, hydrocele, and frequent acute attacks. LF has one of the largest disabilities in terms of years lived with disability (YLDs) and disability weights, particularly in high-prevalence yet low-income nations [11,12]. The psychosocial problems that aggravate the disease development are stigma and social rejection due to poor self-care, delayed treatment, and reduced medical therapy compliance.

These findings are also predetermined by the recent literature [13], and it is also revealed that a low proportion of patients were practicing effective self-care, which worsens physical and overall quality of living. Similar findings indicate that in Ghana and India, other studies were able to demonstrate economic hardship, marginalization in society, and the lack of patient education as the factors that also lead to the decline of well-being [12,14]. The research of different endemic environments [11,15,16] all show that the patients of LF are victims of chronic emotional distress, a lack of social life, and the inability to conduct their everyday activities. These studies bring out quantitative data that justifies the importance of stigma and lack of self-care in increasing the physical burden of the disease.

Gender and Stigma: Women Face Greater Challenges

Women with LF often experience more profound amounts of social stigma when compared with men, mainly due to the ingrained gender roles, social expectations of physical attractiveness, and women’s limited autonomy and decision-making power within their households. The LF visible effects, including swelling, disfigurement under lymphedema, may critically impact the social, marriageable, and mental health of a woman. In one instance, a woman remarked on the issue of how the individuals in her village avoided interacting with each other willingly as they were afraid of the possibility that the illness was contagious [5,7].

The study of the Indian states of Bihar and Odisha reveals that female patients with LF are more prone to being ashamed, isolated, and burdensome compared to male patients. Twenty-three % of the women surveyed said they avoided public gatherings due to their illness, nearly double the proportion of men at 11%. Also, most women (87%) have to take care of their medical problems by themselves since only 13% reported receiving support from their spouses [11]. It is typical for women in rural Uttar Pradesh to encounter neglect from family, community, and healthcare providers. Conventional rules sometimes make it necessary for them to get consent before getting medical care, and this adds another obstacle for patients.

How Stigma Leads to Treatment Failure

Due to the social stigma linked to LF, patients often delay seeking help, which makes their physical condition worse and causes even greater emotional harm [12]. In Sri Lanka, research revealed that those infected with LF suffered from rejection and emotional pain as the disease was very visible. Such a negative view caused people to avoid getting medical help which made their condition worse [13]. A similar situation was seen in the Buvuma and Napak districts of Uganda, where affected individuals told of being rejected or abandoned by people in their communities. As a result of these negative thoughts in society, affected individuals started to feel abandoned, had low self-esteem, and found it hard to trust professionals, all caused by the strong beliefs in their culture. Stigma is especially worrisome because it leads to mental health problems [14]. Living with LF increases the chance of depression and anxiety and reduces the quality of life. According to this study, in both countries, women who experience LF-related disabilities showed serious mental problems, mainly due to the stigma and social punishment they experience.

Moreover, the condition is greatly influenced by people’s feelings of shame. Sometimes, people with an illness become ashamed, which may prevent them from visiting doctors or hospitals, as they are afraid of what others will say. Thus, this problem leads to late diagnoses and reduces patients’ ability to stick to long-range plans. As a result, people with untreated or inadequately managed LF may experience worsened health effects and less happiness in their lives. Because of the fear that society will judge them, they do not receive support, and the situation worsens, making the bias in society stronger (Figure 1). Avoiding this requires health education, public campaigns, and community resources that make visiting the doctor comfortable for all [15].

Figure 1.

Cycle of stigma affecting the outcome of the disease.

Health-Economic Considerations

Addressing LF extends beyond medical and psychosocial management, as the disease imposes substantial economic burdens on patients, families, and health systems. Studies have shown that LF-related disability reduces productivity, increases healthcare costs, and limits social participation, compounding the psychosocial impact [16-18]. Recent cost-effectiveness analyses emphasize that optimizing MDA strategies can significantly improve resource allocation. For example, a recent study [6] has demonstrated that lowering the antigen prevalence threshold for stopping MDA from <1% to <0.5% increases the probability of elimination. Although this may slightly increase short-term costs due to additional treatment rounds, it is cost-effective in the long term when measured using DALYs averted. Similarly, another study [19] has demonstrated that early and targeted implementation of IDA can reduce overall program costs by preventing future disability and minimizing repeated treatment cycles. These findings highlight the economic rationale for integrating clinical, psychosocial, and monitoring strategies, supporting a holistic approach to LF elimination while aligning with SDG targets for reducing neglected tropical disease burden by 2030.

Global Perspective and Lessons Learned

While India bears a significant proportion of the global LF burden, experiences from other endemic countries provide valuable lessons. In Sri Lanka, a combination of high-coverage MDA, community engagement, and strong monitoring led to the successful elimination of LF as a public health problem in 2016 [20]. Similarly, several African countries, including Togo and Malawi, have achieved national elimination targets through sustained MDA campaigns, rigorous mapping, and inclusion of disability management programs [21]. In Uganda and Nigeria, progress has been more uneven due to challenges such as low MDA coverage, poor community compliance, and logistical difficulties in reaching remote populations [22]. Recent WHO reports [23] indicate that while many countries achieve over 70-80% MDA coverage, adherence remains a barrier in areas with social stigma, seasonal migration, or limited health infrastructure. These global experiences demonstrate that combining high MDA coverage with community education, stigma reduction, and integrated care is critical for accelerating LF elimination and improving patient outcomes worldwide. Lessons from successful countries can guide regional strategies in India and other high-burden areas.

Ways to Overcome the Stigma

To overcome the negative opinions about LF, efforts must address the social, cultural and psychological aspects of the illness (Table 1). Even though LF has been well-controlled through MDA and dealing with its carriers, it is now necessary to include efforts to reduce stigma and ensure all people receive the care they need.

Table 1. Summary of Various Stigma, their Impacts, and Intervention Methods to Overcome.

Domain	Impact	Interventions / Mitigation Strategies	Key Outcome
Physical	Chronic lymphedema, acute adenolymphangitis, hydrocele, and disability	Mass Drug Administration (DEC, Ivermectin, Albendazole, IDA); Surgical management; Self-care programs	Reduced swelling, fewer acute attacks, slower disease progression, improved mobility
Psychological	Anxiety, depression, low self-esteem, and social withdrawal	Counselling, peer support, psychosocial therapy, mental health integration	Improved mental well-being, increased healthcare-seeking behavior, and adherence to treatment
Social	Stigma, discrimination, social exclusion, reduced work/marriage opportunities	Community education, awareness campaigns, gender-sensitive programs, legal/policy support, and disability recognition	Reduced stigma, better community acceptance, increased participation in MDA, improved social functioning
Economic/ Health System	Loss of productivity, financial burden on families, and increased healthcare costs	Cost-effective MDA strategies, monitoring & evaluation, financial aid programs, integrated LF programs	Improved adherence, reduced DALYs/YLDs, long-term cost savings

In 2018, the Indian government officially announced that LF would henceforth be considered a physical impairment that falls within the definition of “locomotor disability.” This acknowledgement makes it possible to include LF patients in the disability framework described in “The Rights of Persons with Disabilities (RPwD) Act, 2016” [24]. When lymphedema due to LF becomes a recognized disability, it reduces the stigma that those dealing with it experience. A disease being formally recognized as a disability encourages people to understand it as a significant health matter instead of blaming it on lazy or superstitious behavior. This means patients might be eligible for financial help, free treatment, and work benefits which help them preserve their independence and dignity. It ensures that there is no unfair treatment for individuals inside workplaces, schools, and our communities.

1. Community Education and Awareness

Education campaigns that correct misconceptions about LF not only reduce fear and stigma but also encourage timely participation in MDA programs. Evidence shows that communities with higher awareness report improved MDA coverage and adherence, which directly reduces microfilarial prevalence and prevents new infections. Schools, local leaders, and health workers play a pivotal role in disseminating accurate information and promoting preventive hygiene practices.

2. Integrating Mental Health Support

Counseling, peer support, and psychosocial therapy help patients overcome anxiety, depression, and social isolation. By reducing fear of judgment, these interventions improve patient engagement with healthcare, leading to earlier reporting of lymphedema, timely management of acute attacks, and better adherence to prescribed medications. This directly reduces morbidity and slows disease progression.

3. Empowering Patients Through Self-care Programs

Structured limb-care routines, including hygiene, exercise, and prompt treatment of secondary infections, decrease swelling and prevent episodes of acute adenolymphangitis. Recent studies [25-27] show that patients trained in self-care experience fewer acute attacks, slower progression of lymphedema, and improved quality of life. By combining self-care education with psychological support, adherence improves, and DALYs are reduced.

4. Addressing Gender-Specific Challenges

Women-centered interventions, such as self-help groups, gender-sensitive counseling, and vocational training, empower female patients to seek care early and consistently. Ensuring women can access healthcare without needing family permission or fear of social repercussions improves treatment adherence and early lymphedema management, directly lowering morbidity.

5. Improving Access to Health Services

Mobile clinics, trained community health workers, and regular MDA campaigns increase the reach of treatment services, particularly in rural and underserved areas. When combined with stigma-reduction strategies, more patients present for early diagnosis and management, reducing disease progression and preventing severe disability.

6. Legal and Policy Interventions and Collaboration

Anti-discrimination policies, integration of LF into disability frameworks (eg, RPwD Act, 2016), and social protection programs not only improve societal acceptance but also facilitate access to treatment and financial support, which encourages adherence to both pharmacological therapy and self-care routines. Coordinated action among governments, NGOs, and health systems ensures these benefits are sustained.

Conclusion

The stigma surrounding LF affects patients beyond the physical disease. The consequences of this are shame, withdrawal, discrimination, and financial difficulties for those who deal with it, making their lives difficult. This stigma often arises from ignorance, cultural beliefs, and visible disfigurement. We discovered that lowering the stigma matters as much as treating the condition. Therefore, we must spread information, support affected individuals through community programs, integrate them into disability welfare schemes, and ensure accessible treatment. Addressing both health and social needs in LF helps patients preserve their dignity and reintegrate into society.

Glossary

LF

Lymphatic filariasis

MDA

mass drug administration

NTD

neglected tropical disease

DEC

diethylcarbamazine

IDA

ivermectin, DEC, and albendazole

DALYs

disability-adjusted life years

Author Contributions

AS: Conceptualization, literature search, literature writing; PK: Literature writing, literature editing.